AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Identification of stem cells as the cellular basis of prostate cancer provides therapeutic potential

Summary: Michael M. Shen, Ph.D..

Technology Benefits: Previously unidentified stem cell type in prostate endothelium Stem cell type is physiologically relevant to human prostate cancerExhibits oncogenic properties faithful to disease phenotype Patent information:Patent Pending (US20110045053)Tech Ventures Reference: IR 2624

Technology Application: Diagnosis of prostate cancer and prostate cancer riskPotential target for the development of therapeutics for prostate cancerBasis of in vitro high throughput assays for drug and biomarker development

Detailed Technology Description: Michael M. Shen, Ph.D..

*Abstract: None

*Inquiry: Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR: 2624

*Principal Investigator

*Publications: Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM. "A luminal epithelial stem cell that is a cell of origin for prostate cancer." Nature. 2009 Sep 24;461(7263): 495-500.Wang ZA, Toivanen R, Bergren SK, Chambon P, Shen MM. "Luminal Cells Are Favored as the Cell of Origin for Prostate Cancer." Cell Rep. 2014 Aug 27; S2211-1247(14): 00661-5

Country/Region: USA

For more information, please click Here